Cargando…
Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial
BACKGROUND: Evidence suggests a role for excessive inflammation in COVID-19 complications. Colchicine is an oral anti-inflammatory medication beneficial in gout, pericarditis, and coronary disease. We aimed to investigate the effect of colchicine on the composite of COVID-19-related death or hospita...
Ejemplares similares
-
Critical Appraisal of C-Reactive Protein Throughout the Spectrum of Cardiovascular Disease
por: Osman, Raed, et al.
Publicado: (2006) -
Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19
por: Tardif, Jean-Claude, et al.
Publicado: (2022) -
Genetics of symptom remission in outpatients with COVID-19
por: Dubé, Marie-Pierre, et al.
Publicado: (2021) -
Childhood maltreatment and leukocyte telomere length in men and women with chronic illness: an evaluation of moderating and mediating influences
por: Connor, Alexandra, et al.
Publicado: (2023) -
In Vivo Near-Infrared Fluorescence Imaging of Atherosclerosis Using Local Delivery of Novel Targeted Molecular Probes
por: Bertrand, Marie-Jeanne, et al.
Publicado: (2019)